Abstract: The invention relates to compounds, compositions, and methods for the treatment of lupus. The compounds of the present invention are isoLG savaging compounds.

Abstract: The invention relates to compounds, compositions, and methods for the treatment of lupus. The compounds of the present invention are isoLG savaging compounds.

Abstract: A method of treating at least one of inflammation, psoriasis, and/or hypertension comprising administering to a patient in need there of an effective gamma-ketoaldehyde scavenging amount of a gamma-ketoaldehyde scavenging compound.

Abstract: A method of treating at least one of inflammation, psoriasis, and/or hypertension comprising administering to a patient in need there of an effective gamma-ketoaldehyde scavenging amount of a gamma-ketoaldehyde scavenging compound.

Abstract: Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof.

Abstract: Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof.

Abstract: A method of treating at least one of inflammation, psoriasis, and/or hypertension comprising administering to a patient in need there of an effective gamma-ketoaldehyde scavenging amount of a gamma-ketoaldehyde scavenging compound.

Abstract: The cloning, nucleotide and deduced amino acid sequences of the gene encoding endothelial nitric oxide synthase are described. The sequence contains binding domains for calcium/calmodulin, FMN, FAD and NADPH. The enzyme has a molecular weight of 133,413 M.sub.r. The amino terminal portion of the enzyme exhibits a proline-rich region and several sites for proline-directed phosphorylation as well as a potential substrate site for acyl transferase. DNA probes prepared from the nucleic acid sequence are useful in research and diagnostically to determine the level of nitric oxide synthase mRNA expressed by endothelial cells both in cell culture and in intact tissues. These probes are also useful for detecting genetic abnormalities. The nitric oxide synthase gene is transfected into blood vessels in vivo for enhanced synthesis of nitric oxide synthase, resulting in increased production of nitric oxide.